NOAC for Patients with AF and ACS.
10.18501/arrhythmia.2016.006
- Author:
Dong Hyeok KIM
1
;
Jong Il CHOI
Author Information
1. Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine and Korea University Medical Center, Seoul, Korea. jongilchoi@korea.ac.kr
- Publication Type:Review
- Keywords:
Atrial Fibrillation;
Acute Coronary Syndrome;
Stroke;
Bleeding;
Anticoagulants;
Antiplatelet Agent
- MeSH:
Acute Coronary Syndrome;
Anticoagulants;
Atrial Fibrillation;
Hemorrhage;
Humans;
Platelet Aggregation Inhibitors;
Stroke
- From:International Journal of Arrhythmia
2016;17(1):41-45
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Atrial fibrillation (AF) can occur in acute coronary syndrome (ACS), which is a serious medical condition and may require the use of antiplatelet agents in addition to anticoagulants for stroke prevention. Recently, novel or non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly used for stroke prevention in patients with AF instead of traditional OACs. The duration of treatment or treatment with a stepwise approach (e.g. triple, double, or monotherapy) is determined depending on the clinical setting and the balance between the risks of ischemic stroke and bleeding. However, some concerns and controversies in the use of NOACs in patients with AF and ACS need to be addressed. Here, the current management for NOAC therapy in patients with ACS and AF will be reviewed based on recently published guidelines.
